Cargando…

Capmatinib-Associated Pseudoacute Kidney Injury in Nonsmall Cell Lung Cancer

Detalles Bibliográficos
Autores principales:	Sandoval, Leticia, Radhakrishnan, Yeshwanter, Vaughan, Lisa E., Potter, Ashley, Mansfield, Aaron S., Herrmann, Sandra M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658227/ https://www.ncbi.nlm.nih.gov/pubmed/38025245 http://dx.doi.org/10.1016/j.ekir.2023.08.032

Ejemplares similares

Pattern of bone metastasis in patients with nonsmall cell lung cancer
por: Miyazaki, Kunihiko, et al.
Publicado: (2018)

Management of autosomal dominant polycystic kidney disease in the era of disease-modifying treatment options
por: Radhakrishnan, Yeshwanter, et al.
Publicado: (2022)

Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma
por: Turpin, Anthony, et al.
Publicado: (2023)

Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics
por: Guo, Matthew Z, et al.
Publicado: (2021)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
por: Kunimasa, Kei, et al.
Publicado: (2021)

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
por: Tan, Aaron C, et al.
Publicado: (2021)

Osimertinib in Indian patients with T790M-positive advanced nonsmall cell lung cancer
por: Noronha, Vanita, et al.
Publicado: (2017)

Bone marrow micrometastasis in nonsmall cell lung cancer: A new prognostic marker?
por: Barbetakis, Nikolaos, et al.
Publicado: (2019)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
por: Brazel, Danielle, et al.
Publicado: (2022)

Profile of Capmatinib for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC): Patient Selection and Perspectives
por: Fraser, Madison, et al.
Publicado: (2023)

A rare case of hyperprogression of nonsmall cell lung cancer in a patient on atezolizumab therapy
por: Kollimuttathuillam, Sudarsan Vishnu, et al.
Publicado: (2020)

Osimertinib as an emerging therapeutic modality in nonsmall cell lung cancer: Opportunities and challenges in Indian scenario
por: Thakur, Sayanta, et al.
Publicado: (2020)

New Onset Glomerular Disease Post–COVID-19 Vaccination: Is There a Link?
por: Radhakrishnan, Yeshwanter, et al.
Publicado: (2023)

Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors
por: Sisi, Monia, et al.
Publicado: (2023)

Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer
por: Lim, Jeong Uk, et al.
Publicado: (2014)

Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report
por: Gautschi, Oliver, et al.
Publicado: (2021)

Capmatinib in MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma with Extensive Central Nervous System Metastasis
por: Kim, Tae Woo, et al.
Publicado: (2022)

The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer—A Narrative Review
por: Hsu, Robert, et al.
Publicado: (2023)

Personalised medicine for nonsmall cell lung cancer
por: Mascaux, Céline, et al.
Publicado: (2017)

Modern therapies of nonsmall cell lung cancer
por: Jachowski, Andrzej, et al.
Publicado: (2023)

Risk factors of postoperative acute lung injury following lobectomy for nonsmall cell lung cancer
por: Kim, Hyun Jung, et al.
Publicado: (2019)

Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients
por: Prim, Nathalie, et al.
Publicado: (2014)

Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non–Small-Cell Lung Cancer
por: McCoach, Caroline E., et al.
Publicado: (2021)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Chemotherapy regimens for metastatic nonsmall cell lung cancer: Generating good quality data is important before challenging evidence
por: Kaur, Harpreet, et al.
Publicado: (2016)

TP53 Mutations in Nonsmall Cell Lung Cancer
por: Mogi, Akira, et al.
Publicado: (2011)

Signatures of Drug Sensitivity in Nonsmall Cell Lung Cancer
por: Gong, Hua C., et al.
Publicado: (2011)

The Role of Proteasome Inhibition in Nonsmall Cell Lung Cancer
por: Escobar, Mauricio, et al.
Publicado: (2011)

Gemcitabine for the treatment of advanced nonsmall cell lung cancer
por: Toschi, Luca, et al.
Publicado: (2009)

Thyroid Metastasis from Nonsmall Cell Lung Cancer
por: Namad, Tariq, et al.
Publicado: (2013)

An IMRT/VMAT Technique for Nonsmall Cell Lung Cancer
por: Zhao, Nan, et al.
Publicado: (2015)

Bronchoscopic treatment of inoperable nonsmall cell lung cancer
por: Kniese, Christopher M., et al.
Publicado: (2020)

Life-Threatening Retroperitoneal Hemorrhage Following Cyst Rupture in Autosomal Dominant Polycystic Kidney Disease (ADPKD): A Case Report
por: Duriseti, Parikshit, et al.
Publicado: (2023)

Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
por: Lin, Chien-Yu, et al.
Publicado: (2022)

Prognostic value of serum high‐density lipoprotein cholesterol elevation in nonsmall cell lung cancer patients receiving radical surgery
por: Luo, Fan, et al.
Publicado: (2020)

Impacts of lung and tumor volumes on lung dosimetry for nonsmall cell lung cancer
por: Lei, Weijie, et al.
Publicado: (2017)

Therapeutic drug monitoring of docetaxel by pharmacokinetics and pharmacogenetics: A randomized clinical trial of AUC‐guided dosing in nonsmall cell lung cancer
por: Ma, Yuxiang, et al.
Publicado: (2021)

Oligometastatic Disease at Presentation or Recurrence for Nonsmall Cell Lung Cancer
por: Gomez, Daniel R., et al.
Publicado: (2012)

Radiofrequency Ablation for Early-Stage Nonsmall Cell Lung Cancer
por: Hiraki, Takao, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_d271ad3f5buc7qt5mos14gq201